This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

47/100

✓ Peer-reviewed alzhub usefulness score 47 out of 100. Tau biomarkers

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Objective To evaluate the performance of Alzheimer disease (AD) cerebrospinal fluid (CSF) biomarkers in a tertiary neurology clinic setting with high frequency of non-AD cases, including normal pressure hydrocephalus (NPH). Methods There were 534 patients who underwent AD CSF biomarkers (Roche Elecsys Aβ42, p-Tau181, total-Tau) from April 1, 2020, through April 23, 2021. A behavioral neurologist blinded to CSF results assigned a clinical diagnosis retrospectively on the basis of consensus criteria, and a neuroradiologist blinded to the diagnosis and CSF studies graded brain magnetic resonance images for indicators of CSF dynamics disorders.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Li, W., Petersen, R. C., Algeciras-Schimnich, A., Cogswell, P. M., Bornhorst, J. A., Kremers, W. K., et al. (2024). Alzheimer Disease Cerebrospinal Fluid Biomarkers in a Tertiary Neurology Practice. Mayo Clinic proceedings. https://doi.org/10.1016/j.mayocp.2023.12.024

Vancouver

Li W, Petersen RC, Algeciras-Schimnich A, Cogswell PM, Bornhorst JA, Kremers WK, et al. Alzheimer Disease Cerebrospinal Fluid Biomarkers in a Tertiary Neurology Practice. Mayo Clinic proceedings. 2024. doi:10.1016/j.mayocp.2023.12.024. PMID: 38935019.

BibTeX

@article{li2024-38935019,
  author  = {Li, W. and Petersen, R. C. and Algeciras-Schimnich, A. and Cogswell, P. M. and Bornhorst, J. A. and Kremers, W. K. and Boeve, B. F. and Jones, D. T. and others},
  title   = {{Alzheimer Disease Cerebrospinal Fluid Biomarkers in a Tertiary Neurology Practice}},
  journal = {Mayo Clinic proceedings},
  year    = {2024},
  doi     = {10.1016/j.mayocp.2023.12.024},
  pmid    = {38935019},
  url     = {https://doi.org/10.1016/j.mayocp.2023.12.024}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

How to read this study

Design: our record does not state a study design, so check the methods section of the original before weighing the result.
Size: the record lists 534 participants. Ask whether that is enough for the question, and who they were.
Effect: the record gives no effect size, so the summary above cannot say how large any difference was.

What the evidence grade means here

This page is graded low. alzhub.org assigns the grade automatically from keywords in the abstract, not from reading the paper. Low means the abstract matched neither pattern. It is the default label, and it does not mean the work is poor; many sound lab and imaging papers land here. It can add at most 5 of the 100 points in the study score, and it is a label about design, not a verdict on whether the findings are true.

New to reading papers? Six questions to ask of any Alzheimer’s study · how we score.

Key findings

Methods There were 534 patients who underwent AD CSF biomarkers (Roche Elecsys Aβ42, p-Tau181, total-Tau) from April 1, 2020, through April 23, 2021.
A behavioral neurologist blinded to CSF results assigned a clinical diagnosis retrospectively on the basis of consensus criteria, and a neuroradiologist blinded to the diagnosis and CSF studies graded brain magnetic resonance images for indicators of CSF dynamics disorders.
Associations between biomarkers, diagnoses, and imaging were assessed by χ 2 , analysis of covariance, and linear regression methods.
Results Median age at time of testing was 67 years (range, 19 to 96 years), median symptom duration was 2 years (range, 0.4 to 28 years), and median Short Test of Mental Status score was 30 (range, 0 to 38).

Why it matters

This study evaluated how Alzheimer's spinal fluid biomarkers performed in a tertiary neurology clinic with many non-Alzheimer's cases, including normal pressure hydrocephalus. It is about diagnostic accuracy in practice and not about treating or curing the disease.

New to this subject? Start with our plain-English guide: Blood tests & biomarkers →

Study details

Participants534
Evidence strengthLow

How this study scored 47/100

Published in a peer-reviewed journal. Scored zero for study design and effect reported because the record does not state it.

Component	Points	Why
Journal tier	7 / 10	Tier 3 — peer-reviewed journal (Mayo Clinic proceedings)
Journal's citation record	3 / 4	Mayo Clinic Proceedings: journal h-index 293 (OpenAlex, 2026-10-29)
Study design	0 / 12	No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence	1 / 5	Rated “low” in our summary
Peer-review validation	10 / 10	Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent	4 / 5	2024 — within 3 year(s) of the newest study here
Sample size	2 / 4	534 participants
Effect reported	0 / 3	No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people	3 / 3	Studied in people (participant count stated)
Randomized / blinded	1 / 2	Blinded or placebo-controlled (as stated in the record)
Times cited	2 / 7	Cited 7 times (OpenAlex, 2026-10-10)
Citations per year	1 / 5	1.8 citations a year over 4 year(s) since 2024
Impact for its field and year	2 / 6	Cited 1.9× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here	1 / 6	Cited by 2 other studies in this library
Still being cited	1 / 4	Cited 7 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record	3 / 4	Last-listed author Jonathan Graff‐Radford: h-index 73 (OpenAlex, whole career)
Institution's track record	2 / 3	Mayo Clinic: institution h-index 1,606 (OpenAlex)
Multicenter collaboration	2 / 3	OpenAlex lists 7 institution(s) in 2 countries
Indexed in PubMed	2 / 2	Indexed in PubMed (PMID 38935019)
Free to read	0 / 2	Behind a paywall — scores zero
Total	47 / 100	—

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 13.

Later studies that cite this one

2 studies in the alzhub library list this one in their references.

Related studies in Tau biomarkers from nearby years

Also tagged “cerebrospinal”

820 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 820 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Tau biomarkers

See all studies in Tau biomarkers →